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Abstract
Background: An increasing prevalence of allergic diseases, such as atopic dermatitis, allergic
rhinitis and bronchial asthma, has been noted worldwide. Allergic asthma strongly correlates with
airway inflammation caused by the unregulated production of cytokines secreted by allergen-
specific type-2 T helper (Th2) cells. This study aims to explore the therapeutic effect of the airway
gene transfer of IL-12, IL-10 and TGF-β on airway inflammation in a mouse model of allergic asthma.
Methods: BALB/c mice were sensitized to ovalbumin (OVA) by intraperitoneal injections with
OVA and challenged by nebulized OVA. Different cytokine gene plasmids or non-coding vector
plasmids were instilled daily into the trachea up to one day before the inhalatory OVA challenge
phase.
Results:  Intratracheal administration of IL-10, IL-12 or TGF-β can efficiently inhibit antigen-
induced airway hyper-responsiveness and is able to largely significantly lower the number of
eosinophils and neutrophils in bronchoalveolar lavage fluid of ovalbumin (OVA) sensitized and
challenged mice during the effector phase. Furthermore, the effect of IL-10 plasmids is more
remarkable than any other cytokine gene plasmid. On the other hand, local administration of IL-4
gene plasmids before antigen challenge can induce severe airway hyper-responsiveness (AHR) and
airway eosinophilia.
Conclusion: Our data demonstrated that anti- inflammatory cytokines, particularly IL-10, have the
therapeutic potential for the alleviation of airway inflammation in murine model of asthma.
Background
Asthma is an immunological disease that has increased
dramatically in prevalence over the past two decades. It is
characterized by airway hyper-reactivity to a variety of spe-
cific and non-specific stimuli, severe chronic airway
inflammation with pulmonary eosinophils, mucus hyper-
secretion, and increased serum IgE levels. Activation of
Th2 cells in the respiratory tract is now believed to be
responsible, in part, for the pathogenesis of this disease.
Th2 cells secreting IL-4, IL-5, and IL-13 have been identi-
fied in the airways of asthmatics [1]. Th2 cytokines pro-
duced in the respiratory tract, airway eosinophilia, high
levels of serum IgE, and mast cell activation [2,3], are all
believed to contribute to the pathological consequences
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inducing airway hyper-responsiveness (AHR), epithelial
damage, and mucus hypersecretion.
Whereas the immunological mechanisms that induce
asthma and allergies are relatively well characterized, the
specific mechanisms that transpire in vivo to downmodu-
late Th2 cell-mediated allergic inflammatory responses
are not yet clear. The Th1-relatived cytokines, such as IL-
12 and IFN-γ, are the candidate cytokines for the treat-
ment of allergic diseases as they downregulate Th2
responses [4]. There is strong evidence regarding the ther-
apeutic effect of Th1 cytokine administration. Using Th1-
related cytokine proteins [5-7] and constructed plasmids
expressing cytokine genes [8-10], airway inflammation
could be decreased. According to our previous study [11],
we also demonstrated that the local transfer of the IL-12
gene to the respiratory tract could modify allergic inflam-
mation and airway hyper-responsiveness (AHR). How-
ever, recent studies have shown that not only Th1-related
cytokines, but also other anti-inflammatory cytokines,
including TGF-β and IL-10, can downregulate Th2
responses and might also play an important role in regu-
lating pulmonary inflammation and asthma [12,13]. IL-
10 and TGF-β, which are pleiotropic cytokines with signif-
icant anti-inflammatory and immunosuppressive proper-
ties, are key regulators in the maintenance of
immunological homeostasis. In humans, relative under-
production of IL-10 by alveolar macrophages and in the
sputum of patients with asthma has been reported
[14,15], which suggests an essential role IL-10 in regulat-
ing airway inflammation. In addition, TGF-β inhibits the
production of proinflammatory cytokines from macro-
phages, B cells, and T cells and is a potent inhibitor of T
cell-mediated immune responses, both in vitro [16,17]
and in vivo [18,19]. Moreover, TGF-β has been postulated
in the mechanism of oral tolerance, which is mediated by
regulatory T cells that produce TGF-β preferentially
induced at mucosal sites, possibly under the influence of
IL-10 and/or IL-4 [20]. Recently, Hansen et al. showed
that not only TGF-β-producing T cells [21] but also IL-10-
producing T cells [22] could abolish AHR and airway
inflammation in a murine model of asthma. Thus, not
only Th1-related cytokine but also anti-inflammatory
cytokines can regulate airway inflammation. However,
the different effects between these cytokines on alleviating
airway inflammation still need further investigation. The
purpose of the current study was to compare the effect of
four different cytokine genes plasmid including IL-12, IL-
10, and TGF-β on the effector phase of allergen-induced
AHR and airway eosinophilic inflammation.
It is reported that eosinophils are so important in the
asthma, because the toxic products in its granules were
proven to directly damage lung tissue [23]. Amongst eosi-
nophil-active chemoattractants, eotaxin has also been
demonstrated to selectively induce eosinophil recruit-
ment to the airway undergoing allergic reaction [24,25].
In addition, both leukotriene B4 (LTB4) and prostaglan-
din E2 (PGE2) are potent pro- inflammatory mediators
and are involved in several inflammatory diseases [26]. In
this current study, we have compared the levels of eotaxin,
LTB4 and PGE2 in the BALF to investigate the role of
cytokine gene in regulating the production of these
inflammatory mediators and try to address possible
mechanisms for the effect of different cytokine genes.
Methods
Animals
Female BALB/c mice were obtained from and maintained
at the Animal Center of the College of Medicine of
National Taiwan University. Animals were used between
6 and 10 weeks of age and were age-matched within each
experiment. The animal study protocol was approved by
the committee of College of Medicine, National Taiwan
University.
Plasmids and preparation of lipid-plasmid DNA complexes
For the construction of plasmid DNA encoding murine IL-
10 or TGF-β, the cDNA for murine IL-10, or TGF-β was
cloned by reverse transcription- polymerase chain reac-
tion (RT-PCR) from normal mouse spleen cells, using
primers based on the published cytokine sequence. The
cDNA was sequenced and in vitro expression was con-
firmed by enzyme-linked immunosorbent assay (ELISA)
and bioassay (data not shown). The cytokine gene expres-
sion vector utilized the human cytomegalovirus (CMV)
immediate-early promoter and the simian virus 40 (SV40)
polyadenylation sequence. The vector without a gene
insert (empty vector) served as a control for in vivo gene
delivery studies.
The construction of pscIL-12 vectors has been described
previously [27]. Briefly, a linker of 54-bp in length in the
pscIL-12 plasmids connected the p40 and p35 subunits of
the murine IL-12 gene. The p40 and p35 subunits were
obtained by polymerase chain reaction (PCR) from the
BLpSV35 and BLpSV40 plasmids. Recombinant PCR,
using the p40 and P35 PCR products as the DNA tem-
plates and the Sal I-containing and the Bam HI-containing
primers as such primers, generated the single- chain IL-12
genes. The resulting recombinant PCR fragments were
cloned at the Sal I and Bam HI sites of the pCMV vector.
Plasmid DNA was subsequently introduced into the
Escherichia coli DH5α by transformation. The plasmids
were purified using EndoFree plasmid kits (QIAGEN,
Valencia, CA) and suitable for gene therapy.
For intra-tracheal delivery, lipid-DNA complexes were
prepared by combining 15 µl lipofectAMINE (Life Tech-
nologies, Gaithersburg, MD), per 10 µg of plasmid DNARespiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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at a final volume of 15 µl in PBS. The expression of
cytokine plasmid in pulmonary tissues was determined by
the cytokine ELISA of BALF collected 48 hr post- injection
[data not shown, [27]].
Administration of DNA-lipid complexes
Intra-tracheal administration was accomplished by the
use of a No. 23 steel gavage tube and a 1.0-ml syringe. Ani-
mals were anesthetized (pentobarbital sodium salt, Tokyo
Chemical Industry, Tokyo, Japan, 10 mg/ml solution,
0.005 ml/g body weight) prior to intra-tracheal injection
and placed in dorsal recumbence on an inclined board.
The gavage tube was directed into the proximal trachea,
and then the lipid-DNA solution was slowly injected.
Proper positioning of the tube was assured by visualiza-
tion of movement of the fluid meniscus and by palpation
of the gavage tube moving across the tracheal rings. A vol-
ume of 30 µl lipid-DNA mixture was injected intra-trache-
ally, such that each mouse received 10 µg of plasmid
DNA. This technique works well without involving any
surgical procedure and allows the aspirated material to
spread over the whole lung.
Administration of cytokine plasmid into allergen-sensitized 
mice
BALB/c mice were sensitized by an intraperitoneal injec-
tion with OVA (Sigma, St. Louis, MO, 10 µg) complexed
with aluminum potassium sulfate (Imject Alum, Pierce
Biotechnology Inc., Rockford, IL, 2 mg) on day 0. On day
14, the mice were boosted with OVA (30 µg) adsorbed to
alum. As the negative control group, the mice were
injected with PBS only. To examine the therapeutic effects
of different cytokine plasmids, each group of mice
received intra-tracheal delivery of 10 µg pCDNA vector
only or a single chain IL-12 DNA plasmid or TGF-β plas-
mid or IL-10 plasmid liposome complexes, respectively,
two days before the inhalation challenge on day 26 and
28. On day 29, and 30, mice were challenged with OVA
(100 µg in a total volume 40 µl) by intranasal administra-
tion on consecutive days (Fig. 1).
In order to test varying doses of each a single dose of a
cytokine gene, some mice received 2.5 µg IL-10 gene plas-
mid liposome complex (p-IL-10-low) or 20 µg IL-10 gene
plasmid liposome complex (p-IL-10-hi). In the cytokine
gene combination experiment, some mice received 10 µg
IL-10 gene plasmid plus 10 µg single-chain IL-12 gene
plasmid at a final volume of 30 µl DNA-liposome com-
plex (pIL-10 + pscIL-12).
Measurement of airway hyper-responsivenes
Airway responsiveness was measured as a change in func-
tion after challenge with aerosolized mechacholine (Mch)
in conscious, spontaneously breathing animals by baro-
metric plethysmography (Buxco, Troy, NY) as described
in the literature [28]. Pressure differences were measured
between the main chamber of the plethysmograph, con-
taining the animal and a reference chamber (box pressure
signal). Mice were challenged with aerosolized saline (for
the baseline measurement) or Mch (6.25 to 50 mg/ml) for
three minutes and readings were taken and averaged for
three minutes after nebulization. The Penh value for each
minute was recorded and after the third recorded value,
the average Penh value was divided by the Penh of normal
saline and was presented as a relative percentage increase
of Penh.
Analysis of bronchoalveolar lavage (BAL) fluid and lung 
histology
At 48 hours after the last aerosol exposure, all groups of
mice were bled from the retro-orbital venous plexus and
terminated. The lungs were immediately lavaged via the
tracheal cannula with 3 × 1 ml of HBSS, free of ionized
calcium and magnesium. The lavage fluid was centrifuged
at 400 × g for 10 minutes at 4°C. After washing, the cells
were resuspended in 1 ml HBSS, and total cells counts
were determined by counting in a hemocytometer. Cyto-
centrifuged preparations were stained with Liu's stain for
different cell counts. A minimum of 200 cells were
counted and classified as macrophages, lymphocytes,
neutrophils, and eosinophils, based on standard morpho-
logical criteria.
After the lavage, the lungs were immediately removed and
fixed in 10% neutral- buffered formalin, routinely proc-
essed, and embedded in paraffin wax. Five-micrometer
sections were prepared and stained with hematoxylin and
eosin (H&E).
Eotaxin level in bronchoalveolar lavage
The concentration of eotaxin was assayed with an ELISA
kit (R&D Systems Inc., Minneapolis, MN) according to the
manufacturer's instructions. Briefly, the bronchoalveolar
lavage of each condition was added to wells precoated
over- night at 4°C with anti-eotaxin antibody. After two
hours of incubation, the plates were washed and biotin-
Treatment regimen Figure 1
Treatment regimen. Time line representation of the OVA 
protocol used and the intratracheal injection of cytokine 
plasmid. i.p., intraperitoneal; i.t., intra-tracheal.Respiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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conjugated antibody was added. After two more hours at
room temperature, HRP-avidin was then added, and the
OD (at 450 nm) values were converted to concentrations
of chemokine in the BALF. The sensitivity of this assay was
1.9 pg/ml for eotaxin.
Measurement of cytokines
Quantifications of IL-10, IL-12, and TGF-β in the BAL flu-
ids were evaluated using commercially available ELISA
kits (Duoset, R & D, Minneapolis, MN, USA). Briefly, the
BAL fluids were added to wells pre-coated over night at
4°C with anti-cytokine Ab. After 2 hours of incubation,
the plates were washed and biotin-conjugated Ab was
added. After two more hours at room temperature, HRP-
avidin was added to each well. The substrate tetramethyl-
benzidine was then added and the OD (at 450 nm) values
were converted to concentrations of cytokines in the BAL
fluids. The sensitivity of this assay was 31.3 pg/ml for IL-
10, IL-12 and TGF-β.
Quantification of PGE2 and LTB4
PGE2 or LTB4 levels in the BALF were determined using
the PGE2 enzyme immunoassay kit or LTB4 enzyme
immunoassay kit (Assay Designs, Inc., Ann Arbor, MI)
according to the manufacturer's instructions. The detec-
tion limits for PGE2 and LTB4 are 39 and 47 pg/ml,
respectively.
Statistical analysis
Data are expressed as the mean ± SEM for each group. The
statistical significance of the differences between various
treatment groups was assessed with the Mann-Whitney U
test for non-parametric data.
Results
The effect of different cytokine genes on methacholine-
induced increase in AHR and airway eosinophilia
In order to examine the effect of different cytokine genes,
lipid- plasmid DNA complexes were administered intrat-
racheally 48 hours prior to OVA challenge in OVA-sensi-
tized mice. One day after the last allergen challenge, each
group of mice was measured for airway responsiveness to
aerosolized methacholine (Figure 2). We measured the
extent of airway constriction of mice using the Buxco sys-
tem. The Penh (pause of enhance) increased as the con-
centration of methacholine increased. The mice sensitized
with OVA but only administered mock vector-only devel-
oped marked increased airway responsiveness to metha-
choline challenge compared with mice challenged
without prior sensitization. We also immunized the mice
with OVA only without any delivery of DNA plasmid as
the control. Actually the severity of airway inflammation
was very similar between these two groups.
To further assay the cytokine levels in BAL fluids (BALFs)
of mice received cytokine genes treatment. BALFs col-
lected from control and cytokine gene-treated mice were
analyzed with sandwich-ELISA. The results showed that
the level of IL-12 (365.0 ± 111.9 pg/ml vs. 85.7 ± 16.1 pg/
ml), IL-10 (453.6 ± 99.2 pg/ml vs. 66.4 ± 22.6 pg/ml) and
TGF-β (1110.6 ± 47.2 pg/ml vs. 166.0 ± 25.5 pg/ml)
increased in individual cytokine gene delivered mice com-
pared to the control mice respectively.
Similar to our previous study [11], local administration of
single- chain IL-12 gene plasmids exerted the therapeutic
Effect of different cytokine genes on methacholine- induced  increases in airway hyperresponsiveness (AHR) Figure 2
Effect of different cytokine genes on methacholine- 
induced increases in airway hyperresponsiveness 
(AHR). Mice were treated as described in Figure 1. One day 
after the last OVA challenge, AHR was measured in response 
to increasing concentrations of methacholine (0–50 mg/ml) in 
conscious mice placed in a whole-body plethysmograph. 
"Negative control" mice were mice that were sensitized and 
challenged with normal saline. Both "positive control" mice 
and "vector-only" mice were mice that immunized and chal-
lenged with OVA. However, only the "vector-only" group 
was treated with mock DNA plasmid. Data are representa-
tive of three separate experiments with similar results. The 
columns and error bars represent mean ± SEM for each 
group. * P < 0.05, ** P <0.01 as compared with the vector-
only treated control groupRespiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
Page 5 of 14
(page number not for citation purposes)
effect in OVA-induced asthma model as in the Der p 1-
induced asthma model. Further, administration of TGF-β
gene plasmids and IL-10 gene plasmids has also been
found to inhibit the increase in airway responsiveness to
methacholine after aerosol challenge in OVA-sensitized
mice when compared with that of the mock vector-only
group.
Further, we analyzed the cellular composition in the BAL
fluid of sensitized mice 48 hours after the last challenge to
determine whether the local transfer of cytokine gene
plasmids could alleviate airway inflammation. In positive
control group mice, exposure to aerosolized OVA often
induced a marked increase in the number of neutrophils
and eosinophils in BALF (Figure 3). In contrast, a few cells
were noted in non-sensitized mice. The delivery of vector-
only plasmid did not decrease the airway inflammation in
murine model of asthma. However, administration of
scIL-12-encoding vector partially decreased the recruit-
ment of eosinophils (p = 0.12) compared to the vector-
only treated group. A similar result was also found in mice
treated with TGF-β and IL-10-encoding vector, although a
certain degree of variance was noted. Administration of
IL-10 gene plasmids (p = 0.009) had a more significant
Effects of different cytokine gene plasmids on airway eosinophilic inflammation in mice after aerosol challenge Figure 3
Effects of different cytokine gene plasmids on airway eosinophilic inflammation in mice after aerosol challenge. 
Mice were treated as described in Figure 1. Two days after the last OVA challenge, mice were sacrificed, and the bronchoalve-
olar lavage fluid (BALF) was collected. The cell compositions in BALF of different groups of mice were analyzed. Data are rep-
resentative of three separate experiments with similar results. The columns and error bars represent mean ± SEM for each 
group. * P < 0.05, ** P < 0.01 as compared with the vector-only treated control groupRespiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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decrease in the level of eosinophilia than those given TGF-
β (p = 0.04) and IL-12 (p = 0.12) encoding vector. Further-
more, the recruitment of neutrophils was almost com-
pletely inhibited by the treatment of IL-10 encoding
vector (p = 0.019).
Histopathologically, many cells infiltrated around the
bronchial and lung alveoli in both the control (data not
shown) and vector treated group (Fig. 4B); in the contrast,
the damage and infiltrative cells were less severe in the
scIL-12 plasmid (Fig. 4C) or TGF-β plasmid (Fig. 4D) or
IL-10 plasmid treated group (Fig. 4E). These results dem-
onstrated that intratracheal delivery with scIL-12 plasmid;
TGF-β plasmid or IL-10 plasmid could efficiently inhibit
the infiltration of the cells and reduce the pathological
damage within the lung in this mouse model.
We also examined whether the level of OVA-specific
serum antibodies were affected by the treatment of differ-
ent cytokine gene plasmids (data not shown). Ovalbu-
min-sensitized mice had increased total serum IgE
concentrations and produced OVA-specific IgE and IgG1
antibodies after airway challenge with OVA. However,
only low levels of OVA-specific IgG2a were detected in
serum. Intra-tracheal administration of mock vector DNA
did not change OVA-specific antibody levels. The OVA-
specific IgE concentrations were also increased, but the
increase was not significant. Furthermore, administration
of scIL-12, IL-10, or TGF-β plasmid DNA did not signifi-
cantly change OVA-specific IgE, IgG1, or IgG2a levels in
serum.
The effect of different cytokine gene plasmids on eotaxin 
and leukotriene B4 (LTB4) levels in BAL fluid
In order to investigate the effects and underlying mecha-
nism(s) of the action of different cytokine gene plasmids
on eosinophils recruitment, the inflammatory mediators
implicated in regulating eosinophils accumulation was
also determined. Allergen challenge via the airway in sen-
sitized mice resulted in a sharp increase in eotaxin levels
in BALF (P = 0.005, compared with the negative control).
In our previous in vitro study, Ye et al. [29] have demon-
strated that IL-4 could stimulate lung cells to secret
eotaxin, but IL-12 could suppress eotaxin secretion from
IL-13 or IL-4 stimulated primary lung cell culture. In
present study, in vivo experiment also supported this
result. Administration of scIL-12 gene plasmid could
decrease the level of eotaxin in the BALF. Furthermore, the
eotaxin levels in BAL fluid significantly decreased through
the delivery of IL-10 (P = 0.019) and TGF-β encoding vec-
tor (P = 0.007) in OVA- sensitized mice (Figure 5). The
data showed that the eotaxin levels correlate with the
reduction in eosinophils in BALF.
LTB4 and PGE2 are potent eicosanoid lipid mediators that
are involved in numerous homeostatic biological func-
tions and inflammation [26]. The interaction between
eicosanoid may represent means to regulate the release of
inflammatory mediators, and may be important for the
regulation of cell functions and inflammatory disorders,
such as allergic asthma. Previous studies have reported
that PGE2 could enhance the production of endogenous
IL-10, which inhibits LTB4 production. In this study, the
levels of LTB4 and PGE2 in the BAL fluid were also deter-
mined after administration of different cytokine gene
plasmid. The level of LTB4 and PGE2 in BAL fluid did not
show a significant difference among groups treated with
different cytokine gene plasmids. However, LTB4 concen-
trations in the BAL fluid of the IL-10 gene-treated group
was obviously lower than that of vector-only treated
group (p = 0.085). This result was proven that IL-10 gene
plasmid could decrease the production of LTB4 as previ-
ous study.
Dose-dependent effect of IL-10 gene plasmid in the 
suppression of AHR and airway eosinophilic inflammation 
in OVA-sensitized mice
We next decided to investigate the relative efficacy of var-
ying doses of IL-10 gene plasmid for the alleviating effect
of the severity of asthma symptom. Mice were sensitized
and boosted as previous experiment. On day 27 and 28,
some mice received different doses of IL-10 gene plasmid
liposome complex by intra-tracheal injection before the
last challenge. The results of experiments are shown in
Figure 6. It is apparent that the immune- modulating effi-
cacy is correlated with the administrated dose of IL-10
plasmid. Intra-tracheal delivery of related less amount of
IL-10 plasmid did not have any effect on the suppression
of AHR and airway eosinophils recruitment. However, in
mice that received the same amount of IL-10 gene plasmid
as above in pIL-10-med group, the severity of airway
hyper- responsiveness (p = 0.0022) and eosinophilia (p =
0.026) was significantly decreased. Moreover, while the
administration dose was 2-fold amount, the suppressive
effect of IL-10 gene plasmid was markedly increased. In
pIL-10-hi group mice, high dose IL-10 gene delivery
almost completely diminished the eosinophil number in
BALF (p= 0.0179) and AHR to methacholine was also
decreased (p = 0.0179, compared to the positive control
group). These results indicated that in vivo IL-10 gene
delivery suppressed Ag- induced eosinophilic airway
inflammation and AHR in a dose-dependent manner.
Combination effect of IL-10 and IL-12 gene plasmid in the 
suppression of AHR and airway eosinophilic inflammation 
in OVA-sensitized mice
As described above, not only scIL-12 plasmid but also IL-
10 plasmid could efficiently inhibit the infiltration of the
inflammatory cells and reduce the pathological damageRespiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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Histological studies of the lungs of immunized mice with different cytokine gene plasmid treatments Figure 4
Histological studies of the lungs of immunized mice with different cytokine gene plasmid treatments. Mice that 
had been sensitized and repeatedly challenged with nebulized saline (A) or OVA (B-E) were gavaged with non-coding vector, 
scIL-12, TGF-β, or IL-10 gene plasmids before the challenge phase. The data showed extensive cellular infiltration of the peri- 
airway region from vector DNA treated mice (B). In contrast, lung tissue from scIL-12 plasmid treated mice (C), TGF-β plas-
mid treated mice (D), and IL-10 plasmid treated mice (E) showed a much less severe inflammation histologically. Microscopic 
images were made with an Olympus microscope at a magnification of 100, and images were representative of the experimental 
group. Paraffin embedded sections were stained with hematoxylin and eosin.Respiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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within the lung though intra-tracheal gene delivery. How-
ever, it has been reported that IL-10 can inhibit
Th1cytokine production via the suppression of IL-12 syn-
thesis in accessory cells [30]. In our present study, we
examined the effect of IL-10 gene plasmid and single
chain IL-12 gene plasmid, alone or together on the mod-
ulation of the airway inflammation of OVA- sensitized
mice. As shown in Fig. 7A, AHR to Mch was significantly
decreased in mice treated with pIL-10 (p = 0.0022) or psc-
IL-12 alone (p = 0.0476). Furthermore, the recruitment of
eosinophils in the BALF was also inhibited in both pIL-10
(p = 0.026) and pscIL-12-treated mice (p = 0.0079) (Fig.
7B). These results were similar to our previous experi-
ment. The combination treatment of IL-10 gene and sin-
gle-chain IL-12 gene plasmid also suppress the airway
eosinophilic inflammation (p = 0.0278) (Fig. 8B). How-
ever, the effect on the suppression of AHR was not as effi-
cient as the mice which received IL-10 gene plasmid or
single-chain IL-12 gene plasmid alone.
Discussion
Allergic diseases are characterized by the presence of Th2
cells and related cytokines, such as interleukin-4 (IL-4),
IL-5, IL-9, and IL-13 with the subsequent development of
eosinophils infiltration and chronic inflammation.
Although the immunologic mechanisms that induce
asthma and allergic diseases are relatively well character-
ized, the specific mechanisms that transpire in vivo to
down-modulate Th2-mediated allergic inflammatory
responses are yet to be clarified. However, blocking the
release or effects of pro-inflammatory cytokines in allergic
asthma has provided the basis for the development of
novel treatments [12]. In this study, we employed a lipo-
some-mediated genetic transfer approach to examine the
therapeutic efficacy of the local pulmonary delivery of var-
ious cytokine gene plasmids in the same murine model of
asthma in OVA-sensitized mice.
First, we demonstrated that intra-tracheal delivery with
scIL-12 plasmid; TGF-β plasmid or IL-10 plasmid could
suppress Ag-induced eosinophilic airway inflammation
and airway hyper- responsiveness during Ag challenge, an
effector phase of the immune response (Fig. 1 and 2). On
the other hand, administration of IL-4 plasmid enhanced
the severity of airway inflammation.
It is complex in the control of allergic inflammation and
asthma, which are involving several different mechanisms
and several different cell types and cytokines. Neverthe-
less, several studies have demonstrated that IL-12 protein
can decrease allergen-specific IgE and eosinophils infiltra-
tion in a mouse model of airway inflammation [5,6,9,31].
Previous studies have shown that intravenous injection of
single chain IL-12 DNA plasmids mixed with liposome
achieved the highest protein expression in the lungs and
can alleviate airway hyper-responsiveness in an animal
model of asthma [32]. Furthermore, the local IL-12 gene
transfer to the lung before the tracheal allergen challenge
resulted in a remarked decrease in IL-5 levels and a simi-
larly marked increase in IFN-γ, this being consistent with
a shift from a Th2 to a Th1 profile [11]. The results of our
present study also support the finding that intra-tracheal
delivery of IL-12 encoding DNA plasmids can decrease
eosinophils infiltration in a murine model of airway
inflammation.
Both TGF-β and IL-10 are pleiotropic cytokine with signif-
icant anti-inflammatory and immuno-modulatory prop-
erties. Thus, we investigated the suppressive effect of these
two cytokines in modulating pulmonary inflammation
and asthma. TGF-β is a key immunoregulatory factor in
Effect of different cytokine gene plasmids on eotaxin and  LTB4 levels in BAL fluid from mice after aerosol challenge Figure 5
Effect of different cytokine gene plasmids on eotaxin 
and LTB4 levels in BAL fluid from mice after aerosol 
challenge. Two days after the last OVA challenge, mice 
were sacrificed, and the BAL fluid was collected. Eotaxin lev-
els in BALF of different groups of mice were measured by 
ELISA. Data are representative of three separate experi-
ments with similar results. The columns and error bars rep-
resent mean ± SEM for each group. * P < 0.05, ** P <0.01 vs. 
vector-only treated control groupRespiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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Intra-tracheal delivery of IL-10 gene plasmid can suppress AHR and airway eosinophilic inflammation in OVA-sensitized mice in  a dose-dependent manner Figure 6
Intra-tracheal delivery of IL-10 gene plasmid can suppress AHR and airway eosinophilic inflammation in OVA-
sensitized mice in a dose-dependent manner. Mice were sensitized and boosted as described in Fig. 1. On day 27 and 28, 
some mice received different doses of IL-10 gene plasmid DNA liposome complex by intra-tracheal injection (pIL-10-low: 2.5 
µg; pIL-10-med: 10 µg; pIL-10-hi: 20 µg). Then, mice were challenged with 100 µg OVA by intranasal administration on day 29, 
and 30. On day 31, mice were analyzed. (A) AHR to Mch was measured as described in Material and Methods (n= 4–7 per 
group). The columns and error bars represent mean ± SEM for each group. * P < 0.05, ** P <0.01 compared with the value of 
positive controlgroup. (B) Bronchoalveolar lavage fluid (BALF) was collected two days after the last OVA challenge of each 
group of mice (n = 4–7). The cell compositions in BALF were analyzed. The columns and error bars represent mean ± SEM for 
each group.Respiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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Comparison of the effect of combined administration of IL-10 gene plasmid and IL-12 gene plasmid to the individual treatment  groups on AHR and airway eosinophilic inflammation in OVA-sensitized mice Figure 7
Comparison of the effect of combined administration of IL-10 gene plasmid and IL-12 gene plasmid to the indi-
vidual treatment groups on AHR and airway eosinophilic inflammation in OVA-sensitized mice. Mice were sen-
sitized and boosted as described in Fig. 1. On day 27 and 28, some mice received intra-tracheal injection of IL-10 gene plasmid 
(pIL-10), single-chain IL-12 gene plasmid (pscIL-12), or pIL-10 plus pscIL-12 DNA liposome complex. Then, mice were chal-
lenged with 100 µg OVA by intranasal administration on day 29, and 30. On day 31, mice were analyzed. (A) AHR to Mch was 
measured as described in Material and Methods (n = 5–7 per group). The columns and error bars represent mean ± SEM for 
each group. * P < 0.05, ** P <0.01 compared with the value of positive controlgroup. (B) Bronchoalveolar lavage fluid (BALF) 
was collected two days after the last OVA challenge of each group of mice (n = 5–7). The cell compositions in BALF were ana-
lyzed. The columns and error bars represent mean ± SEM for each group. * P < 0.05, ** P < 0.01 as compared with the positive 
control groupRespiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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the development of unresponsiveness to antigens in the
gastrointestinal tract. TGF-β inhibits the production of
proinflammatory cytokines from macrophages, B cells,
and T cells, and is a potent inhibitor of T cell-mediated
immune responses both in vitro [17,18] and in vivo
[19,20]. Administration of TGF-β diminishes the severity
of autoimmune diseases, such as collagen-induced arthri-
tis [33], allergic encephalomyelitis (EAE) [19], and exper-
imental colitis [34], and neutralization of TGF-β adversely
affects the course of the diseases. Hansen and his col-
leagues [21] have demonstrated that CD4+ T helper cells
engineered to produce TGF-β1 in the respiratory mucosa
can indeed reverse allergen-induced airway hyper-reactiv-
ity and inflammation. TGF-β- secreting T cells, called Th3
cells, have been shown to play a regulatory role at
mucosal sites- e.g., in the induction of oral tolerance [35].
In addition, TGF-β- secreting T cells might also play a sig-
nificant role in modulating allergic inflammation [21].
However, TGF-β is also a potent inducer of myofibroblasts
and collagen synthesis. It has been reported that eosi-
nophils might produce TGF-β to prevent allergen-induced
AHR in late phase [36]. In our study, the result has shown
that administration of TGF-β plasmid in OVA-sensitized
and challenged mice can decrease airway hyper-reactivity,
eosinophilia and neutrophilia. In conclusion, TGF-β may
plays a role in immuno-regulation, wound healing, and to
shorten the inflammatory response when it is applied in
the treatment of allergen-induced asthma.
IL-10 can down-regulate cytokine production not only
from Th1 cells [37] but also from Th2 cells [38]. Borish et
al. [14] reported that asthmatics had a comparatively
decreased ability to produce IL-10 by BALF cells and
mononuclear cells. These associations led to the specula-
tion that constitutive expression of IL-10 in the airway
might contribute to maintain the normal state of allergen
nonresponsiveness. However, the role of IL-10 in regulat-
ing Th2-mediated diseases such as asthma is controver-
sial. Some reports have indicated that IL-10-deficient mice
exhibit exaggerated eosinophilic airway inflammation
provoked by a systemic sensitization to Ag and local inha-
lation of Ag [39,40], whereas another report indicated
that IL-10-deficient mice show diminished eosinophilic
airway inflammation [41]. Indeed, IL-10 is required for
the development of AHR and administration of IL-10
enhanced AHR, though it reduces eosinophilia [42]. The
overall physiologic effect of IL-10 is to decrease inflamma-
tion. It accomplishes this role primarily by down-regulat-
ing synthesis of a number of cytokines, both Th1- and
Th2-associated. The result of our study has shown that
administration of IL-10 plasmids in OVA-sensitized and
challenged mice can decrease airway hyper-reactivity,
including eosinophilia and neutrophilia. These results
support the concept that IL-10 plays a regulatory role in
allergic asthma. As suggested by the effect of IL-10 on air-
way eosinophilia, IL-10 appears to play a role in regulat-
ing eosinophils recruitment. Our findings of a regulatory
role for IL-10 in asthma are strongly consistent with the
idea that IL-10 production mediates Ag-specific tolerance
that protects against allergic diseases and airway inflam-
mation. For example, regulatory T cells producing IL-10
are thought to develop after successful bee venom-specific
immunotherapy [43] and during T-cell tolerance induced
with respiratory exposure to antigen [44,45].
Subsequently, we also compared the level of inflamma-
tory mediators in BALF of OVA- sensitized mice among
different cytokine gene plasmid treated groups. Amongst
eosinophil-active chemoattractants, eotaxin has also been
demonstrated to selectively induce eosinophil recruit-
ment to the airway undergoing allergic reaction [46,47].
Eotaxin is expressed in many different tissues, and may
therefore regulate allergen-induced homing of eosi-
nophils to the site of inflammation. In current study, we
found that eotaxin levels in BAL fluid were significantly
decreased by treatment with IL-10 or TGF-β encoding vec-
tor. It is possible that IL-10 and TGF-β can suppress OVA-
induced airway eosinophils recruitment directly by down-
regulating the production of eotaxin. Although, the
eotaxin level in BALF was not so markedly reduced in the
group of IL-12 gene plasmid treated mice (Fig. 5). How-
ever, it has been reported that IL-12 in regulating eosi-
nophil function by increasing eosinophil apoptosis. On
the other hand, we should consider whether the dose of
IL-12 gene plasmid affects the efficiency of IL-12 gene
plasmid in the inhibiting the airway inflammation.
Moreover, we also detected the level of inflammatory
mediators in the BALF to determine the effect of these
cytokine-encoding vectors. Both leukotriene B4 (LTB4)
and prostaglandin E2 (PGE2) are potent pro- inflamma-
tory mediator, which are involved in several inflamma-
tory diseases [26]. LTB4 is a potent neutrophil
chemoattractant that enhances neutrophil-endothelial
interactions and stimulates neutrophil activation [48].
LTB4 may contribute to airway narrowing by producing
local edema and increasing mucus secretion. The overpro-
duction of LTB4 plays an important role in the pathogen-
esis of asthma and acute lung injury [49]. On the other
hand, the general consensus is that PGs, in particular
PGE2, act to shift the immune response toward a type 2
cytokine profile [50,51]. Moreover, this lipid mediator
can also up-regulate IgE production, and consequently
support the development of type 2 cytokine- associated
inflammatory disorder. However, there is evidence for a
broncho- protective role for PGE2 in asthma [52,53]. In
recent study, Harizi et al. [54] also demonstrated that
PGE2 could inhibit the production of LTB4 from dendritic
cells via IL-10 dependent mechanism. It is not clear
whether PGE2 synthesis in airway diseases can play a del-Respiratory Research 2006, 7:72 http://respiratory-research.com/content/7/1/72
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eterious or a beneficial role. The result of our study indi-
cates that IL-10 can significantly decrease the level of LTB4
in the BALF, but other cytokine gene plasmids may not
show a similar effect (Fig. 5). In contrast, all the cytokines
together do not have any effect on the level of PGE2 in the
BALF (data not shown). Our results may support that IL-
10 could inhibit the recruitment of neutrophils by reduc-
ing the production of LTB4 (Fig. 3).
Further, we have examined varying doses of IL-10 gene
plasmid to test the therapeutic efficiency of this asthma
animal model (Fig. 6). It has been reported that instilla-
tion of IL-10 protein into the lung could suppress eosi-
nophilic inflammation [55,56]. However, the half-lives of
recombinant cytokines are very short and the suppressive
effect is weak. In current study, in vivo IL-10 gene delivery
can efficiently suppress airway eosinophilia (Fig. 3). In
addition, we also demonstrated that IL-10 gene plasmid
had a strong immuno-modulating effect in the suppress-
ing Ag-induced eosinophilic inflammation and AHR in a
dose-dependent manner (Fig. 6).
As IL-10 is a multi-potent immunosuppressive cytokine, it
could exhibit various effects on many resident cells and
inflammatory cells, such as endothelial cells, monocytes/
macrophages, lymphocytes, and mast cells [57,58]. It has
been also reported that IL-10 can inhibits Th1cytokine
production via the suppression of IL-12 synthesis in acces-
sory cells [30]. Thus, we combined 2 plasmids (IL-10 and
IL-12) to treat OVA-sensitized mice (Fig. 7). Our results
showed that in vivo delivery of IL-10 or IL-12 gene alone
could efficiently inhibit AHR and airway eosinophilic
inflammation. However, combination of IL-10 and IL-12
gene therapy did not exert the syngenic effect in the mod-
ulating airway inflammation. It may imply that IL-10 and
IL-12 have some antagonistic effect in the local inflamma-
tory site. In addition, the regulating mechanisms of IL-10
and IL-12 for the suppression of experimental asthma are
totally different. In the recent study of Nakagome K et al.,
they pointed that IL-10 gene delivery can suppress lung
APC functions and the subsequent Th2 response [59]. IL-
10 could reduce the recruitment of eosinophils into the
lung by modulating the expression of VCAM-1 on
endothelial cells [59] and decreasing the secreting level of
eotaxin (in this paper). Thus, IL-10 gene delivery could be
more effective in the treatment of local airway inflamma-
tion.
Collectively, these data suggests that immunosuppressive
cytokines, such as TGF-β and IL-10, as well as Th1-related
IL-12, can alleviate the symptom of airway inflammation
in a murine model of asthma. Table 1 summarizes the
recent studies about the effects of different cytokine in the
treatment of asthma. However, the therapeutic mecha-
nisms of these cytokine gene plasmids are different and
affect different inflammatory mediators. Further investi-
gation is still needed to analyze the further detailed mech-
anisms.
Conclusion
Intra-tracheal administration of TGF-β, IL-10 or IL-12
gene plasmids can efficiently inhibit antigen-induced air-
way hyper-responsiveness and significantly lower the
number of eosinophils and neutrophils in bronchoalveo-
lar lavage fluid of ovalbumin (OVA) sensitized mice dur-
ing the effector phase. Our data demonstrated that anti-
inflammatory cytokines, particularly IL-10, have the ther-
apeutic potential for the alleviation of airway inflamma-
tion in murine model of asthma.
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